Protocol
Low-heat, moist cooking to cut advanced glycation end products (AGEs)
In a 4-week randomized trial in 74 overweight women, a diet cooked to be low in advanced glycation end products (boiling, steaming and stewing instead of frying, grilling and roasting) lowered fasting insulin and insulin resistance compared with a high-AGE diet.
Grade C: human trials exist, but they are small, mixed or not yet repeated. This is not a finding that it does not work. How to read a grade →
At a glance
Cooking with dry high heat, such as frying, grilling and roasting, creates compounds called AGEs. In one month-long trial, overweight women eating food boiled, steamed or stewed instead had lower insulin levels. The trial did not test whether this prevents diabetes.
- What was measured
- Fasting insulin and insulin resistance after 4 weeks.
- How big
- Fasting insulin and HOMA-IR were lower on the low-AGE diet.Read from the summary of PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 23959566.
- Who it applies to
- Overweight women for 4 weeks. Diabetes was not measured.
- Safety
- None identified.
- Compared with
- The same foods cooked by frying, grilling and roasting.
- Certainty
- Grade C, resting on: One randomized trial.
- What would change this grade
- Could rise to B with: Randomized trial of low-AGE cooking. Who: Adults with prediabetes. Measured: HbA1c A blood test that reflects average blood sugar over the previous two to three months. and progression to diabetes. Length: At least 12 months.
- Cost
- No price recorded yet.
- Sources
- 1 study cited on this record, listed under Sources.
- For clinicians
- A one-page summary of this record that prints with a clinician's name and practice, folds to a plain-language patient handout, and gives a chart note to paste into the patient record: Printable summary and chart note.
In a 4-week randomized trial in 74 overweight women, a diet cooked to be low in advanced glycation end products (boiling, steaming and stewing instead of frying, grilling and roasting) lowered fasting insulin and insulin resistance compared with a high-AGE diet. Insulin resistance is not an established stand-in for a clinical outcome, and the trial is unreplicated at this size, so the letter is C.
Why this letter
Why this gradeGrade C, small or unreplicated trials. The reasoning, and what the grade does not cover.
Grade C on insulin resistance. One randomized trial in 74 overweight women found lower fasting insulin and HOMA-IR on a low-AGE diet made by changing cooking method (Mark et al., 2014; PMID 23959566).
WHY NOT BHOMA-IR is not an established stand-in for a clinical outcome, and the result has not been replicated The same finding reproduced by a separate research group. A result seen once can be chance or bias; a replicated one is harder to explain away. in a trial of this size.
WHAT THIS GRADE DOES NOT COVERdiabetes incidence, HbA1c or cardiovascular events, none of which was measured. It also does not cover men, people with diabetes, or the effect of cooking method on cancer risk.
A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →
Who responds: this record's trial reading reports no subgroup that identifies who responds.
Evidence notes: randomized trial
Endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. graded: Insulin resistance (HOMA-IR) (surrogate)
Last reviewed: November 2026
The trial that would change this grade.
A positive trial of this shape, supported by further trials, would move this entry to B.
Why the current trials fall short
HbA1c or diabetes incidence would be a qualifying outcome.
ClinicalTrials.gov, the public registry run by the U.S. National Library of Medicine, lists studies that are recruiting volunteers. The link below searches it for Advanced Glycation End Products among studies recruiting now. EBL has no relationship with any listed study and receives no payment for this link.
Search recruiting studies of Advanced Glycation End Products on ClinicalTrials.gov
Dose, form and timing
Fasting insulin and HOMA-IR.
Safety
No safety data. Each caution on this record, sorted by what it rests on.
None recorded.
None recorded.
None recorded.
None recorded.
No safety data: EBL has found no trial or report of harm for this record. That is an absence of evidence, not a finding of safety.
Grade history
How this letter has changedLatest: No. 443 · November 2026 · First graded.
New record in the food section. In a 4-week randomized trial in 74 overweight women, a diet cooked to be low in advanced glycation end products (boiling, steaming and stewing instead of frying, grilling and roasting) lowered fasting insulin and insulin resistance compared with a high-AGE diet. Insulin resistance is not an established stand-in for a clinical outcome, and the trial is unreplicated at this size, so the letter is C.PMID 23959566
Every change to a letter on this site is dated and published. The full evidence log →
Sources
- Citations
- Every paper cited on this page is matched to its PubMed record on every build.
- Retractions
- None of these papers is retracted or under a journal expression of concern. PubMed is checked again on every build.
- Read against the papers
- November 2026. By a language model (AI-assisted reading), not yet reviewed by a clinician.
- Outside review
- Not yet done. No reviewer outside EBL has checked this record.
What each of these checks can and cannot show: evidence integrity.
The evidence, in fullOne paper, linked to its PubMed record.
Mark et al. (Diabetes Care, 2014; PMID 23959566): parallel randomized trial, 74 overweight women, 4 weeks of high- or low-AGE diet (by cooking method) with fructose or glucose drinks; the low-AGE diet lowered urinary AGEs, fasting insulin and HOMA-IR compared with the high-AGE diet after adjustment for anthropometric change; fructose had no effect.
How EBL searched for the trials (1 search)
The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.
("advanced glycation end product*"[tiab] OR "dietary AGE*"[tiab] OR "low-AGE"[tiab]) AND randomized controlled trial[pt]PubMed watch: does a new study change the grade? (nothing new)
No new paper matching the search behind this grade has been added to PubMed since November 2026.
Last run November 2026. A letter on EBL moves only after a logged review. A new paper never moves a letter by arriving: it is read, the answer is written here, and any change to the letter is published in the evidence log.
For each trial behind a letter on this page, the funding its PubMed record lists. "No funder" means PubMed lists none, not that the trial had no funding.
- Mark et al., 2014, Diabetes Care (PMID 23959566): PubMed lists no funder for this trial.
Disclosure
Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.
Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy
© Evidence Based Longevity, Inc. All rights reserved
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →